Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATP: Regimen Specific Appendix for AADvac1
NCT07167966Phase 2Enrolling by invitation
- Start
- Nov 2026
- Primary completion
- Aug 2028
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of AADvac1 in Alzheimer's disease (AD). Started Nov 2026; status: enrolling by invitation.
02
Drugs
AADvac1
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07167966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07167966.